Product Information
NEOMYC-POLYM-DEXAMET EYE OINTM is a generic product labeled by Sandoz Inc., priced at $2.5513 per GM under NDC 61314063136. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AT.
Strength
1; 3.5; 10000 mg/g; mg/g; [iU]/g
Manufacturer
Sandoz Inc.NDC
61314063136
Classification
Generic
Dosage Form
OINTMENT
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA050065FDA Approved
Before 1982
TE Code
AT
On Market Since
2/21/1996
Pharmacological Classes
Price Statistics
The NADAC for NEOMYC-POLYM-DEXAMET EYE OINTM has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 41.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.5513 per GM |
|---|---|
| All-time high | $4.8575 (Oct 15, 2014) |
| All-time low | $2.1009 (Nov 20, 2024) |
| 52-week high | $2.9358 |
| 52-week low | $2.5513 |
| Median price | $3.2785 |
| Average price | $3.4348 |
| Largest weekly change | +38.7% (Oct 23, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Neomycin and Polymyxin B Sulfates and Dexamethasone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Neomycin and Polymyxin B Sulfates and Dexamethasone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEOMYC-POLYM-DEXAMET EYE OINTM?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYC-POLYM-DEXAMET EYE OINTM, manufactured by Sandoz Inc., is $2.5513 per GM (NDC 61314063136), effective Sep 30, 2026.
How has the price of NEOMYC-POLYM-DEXAMET EYE OINTM changed over time?
Over the history we have for it, the NADAC for NEOMYC-POLYM-DEXAMET EYE OINTM has declined 41.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEOMYC-POLYM-DEXAMET EYE OINTM?
Since Nov 28, 2013, the NADAC for NEOMYC-POLYM-DEXAMET EYE OINTM has ranged from a low of $2.1009 (Nov 20, 2024) to a high of $4.8575 (Oct 15, 2014), with a median of $3.2785 per GM.
Are there cheaper alternatives to NEOMYC-POLYM-DEXAMET EYE OINTM?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYC-POLYM-DEXAMET EYE OINTM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYC-POLYM-DEXAMET EYE OINTM?
NEOMYC-POLYM-DEXAMET EYE OINTM (NDC 61314063136) is labeled by Sandoz Inc., and CMS classifies it as a generic product.